Pegylated granulocyte colony-stimulating factor: all 39 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor ChemoradiotherapyRecruitingNCT07205536Phase 2
• Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJCNot yet recruitingNCT06684158Phase 2
• Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for LymphomaRecruitingNCT06520163Phase 3
• Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple MyelomaRecruitingNCT06060080Not applicable
• Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem CellsRecruitingNCT06026995Phase 4
• The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant MobilizationNot yet recruitingNCT05970185Early Phase 1
• the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in LymphomaNot yet recruitingNCT05834751Not applicable
• Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological MalignanciesRecruitingNCT05536154Not applicable
• Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological MalignanciesRecruitingNCT05510089Not applicable
• A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSFNot yet recruitingNCT05409547Phase 4
• Reverse Triple Negative Immune Resistant Breast CancerRecruitingNCT05076682Phase 2
• A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid MalignanciesWithdrawnNCT06254742Phase 3
• A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte DeficiencyStatus unknownNCT05531279Not applicable
• Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingNCT05463601Phase 2
• G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05222009Phase 1
• PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT05156554Not applicable
• Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical CancerCompletedNCT04542356Phase 2
• PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic CancerStatus unknownNCT04518800Not applicable
• Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic SyndromeStatus unknownNCT04500886Not applicable
• Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological MalignanciesStatus unknownNCT04497701Not applicable
• Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's LymphomaStatus unknownNCT04497688Not applicable
• Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic CancerStatus unknownNCT04239001Not applicable
• Mecapegfilgrastim Prevents Neutropenia and Radiation EsophagitisStatus unknownNCT04171986Not applicable
• Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in LymphomaStatus unknownNCT04083079Phase 4
• Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast CancerCompletedNCT04009941Phase 4
• Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma PatientsStatus unknownNCT03870412Not applicable
• Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian CancerTerminatedNCT03858166Phase 4
• PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving ChemotherapyStatus unknownNCT03776604Not applicable
• To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical CancerStatus unknownNCT03206684Phase 4
• Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult SubjectsCompletedNCT03206229Phase 1
• The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and AdolescentsCompletedNCT02953730Phase 4
• The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive ChemotherapyCompletedNCT02944604Phase 4
• PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT02905942Phase 4
• The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After ChemotherapyStatus unknownNCT02905916Phase 4
• PEG-rhG-CSF in Patients With Lymphoma Receiving ChemotherapyCompletedNCT02805218Phase 4
• PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent NeutropeniaCompletedNCT02805205Phase 4
• PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving ChemotherapyCompletedNCT02805166Phase 4
• PEG-rhG-CSF in Patients With Breast Cancer Receiving ChemotherapyCompletedNCT02805153Phase 4
• The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced NeutropeniaStatus unknownNCT02761460Phase 3

← Pegylated granulocyte colony-stimulating factor overview